$2.26
+0.04 (+1.80%)
Open$2.23
Previous Close$2.22
Day High$2.26
Day Low$2.21
52W High$45.41
52W Low$28.67
Volume—
Avg Volume305.2K
Market Cap208.29M
P/E Ratio17.15
EPS$2.26
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+1,715.9% upside
Current
$2.26
$2.26
Target
$41.04
$41.04
$30.97
$41.04 avg
$66.83
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 29.94M | 31.11M | 33.06M |
| Net Income | -8,740,072 | -8,350,078 | -10,285,734 |
| Profit Margin | -29.2% | -26.8% | -31.1% |
| EBITDA | -14,130,650 | -13,566,183 | -16,328,398 |
| Free Cash Flow | -7,098,906 | -8,976,737 | -6,780,942 |
| Rev Growth | -9.8% | +19.5% | +23.6% |
| Debt/Equity | 0.25 | 0.28 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |